{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/abbott-laboratories-abt/",
 "dataUrl": "https://clearank.com/stock/abbott-laboratories-abt/data.json",
 "title": "Abbott Laboratories (ABT) Stock Forecast (2026)",
 "description": "Abbott Laboratories (ABT) stock: Healthcare, Medical Devices. $178.4B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Abbott Laboratories (ABT)",
 "published": "2026-06-29T09:32:58+00:00",
 "modified": "2026-09-15T11:46:10.655+00:00",
 "generated": "2026-09-16T12:50:29.083Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "ABT",
  "name": "Abbott Laboratories",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Devices",
  "country": "United States",
  "website": "https://www.abbott.com"
 },
 "quote": {
  "price": 103.09,
  "previousClose": 101.95,
  "change": 1.14,
  "changePercent": 1.12,
  "open": 103.56,
  "high": 104.44,
  "low": 102.57,
  "volume": 7791900,
  "averageVolume": 8060790,
  "marketCap": 178385207063,
  "fiftyTwoWeekHigh": 137.49001,
  "fiftyTwoWeekLow": 81.97,
  "marketOpen": false,
  "asOf": "2026-09-15T11:46:10.000Z"
 },
 "statistics": {
  "pe": 33.36246,
  "eps": 3.09,
  "dividendYield": 0.02444228940151284,
  "beta": 0.586,
  "priceToSales": 3.8292413,
  "priceToBook": 3.4901986,
  "revenueTtm": 46584999936,
  "grossMargin": null,
  "returnOnEquity": 0.10576
 },
 "technicals": {
  "rsi": 17.2,
  "macd": -0.9,
  "sma50": 105.45,
  "sma200": 105.72,
  "rsiSignal": "Oversold",
  "trend": "Neutral",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 74,
  "consensus": "Buy",
  "fairValue": 120,
  "analystTarget": 120,
  "analystCount": 26,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-15T11:46:10.000Z",
  "priceAtAnalysis": 103.089996,
  "volatility": {
   "daily": 1.35,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 101.03,
  "aggressiveEntry": 103.09,
  "stopLoss": 97.69,
  "stopLossPercent": 3.3,
  "targets": [
   106.08,
   111.13,
   116.18
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 82.12,
    "base": 111.78,
    "upside90th": 152.16
   },
   {
    "year": 2028,
    "downside10th": 78.37,
    "base": 121.21,
    "upside90th": 187.47
   },
   {
    "year": 2029,
    "downside10th": 77.05,
    "base": 131.44,
    "upside90th": 224.21
   },
   {
    "year": 2030,
    "downside10th": 76.92,
    "base": 142.52,
    "upside90th": 264.06
   },
   {
    "year": 2031,
    "downside10th": 77.55,
    "base": 154.54,
    "upside90th": 307.95
   },
   {
    "year": 2032,
    "downside10th": 78.74,
    "base": 167.58,
    "upside90th": 356.64
   },
   {
    "year": 2033,
    "downside10th": 80.37,
    "base": 181.71,
    "upside90th": 410.85
   },
   {
    "year": 2034,
    "downside10th": 82.37,
    "base": 197.04,
    "upside90th": 471.31
   },
   {
    "year": 2035,
    "downside10th": 84.72,
    "base": 213.65,
    "upside90th": 538.83
   },
   {
    "year": 2036,
    "downside10th": 87.38,
    "base": 231.67,
    "upside90th": 614.25
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "ABT Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$103.56",
    "Day Range": "$102.57 to $104.44",
    "Prev Close": "$101.95",
    "Volume": "7.79M",
    "52-Week Range": "$81.97 to $137.49",
    "Market Cap": "$178.39B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (5% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "ABT Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, ABT beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "ABT Analysis",
   "text": [
    "Abbott Laboratories (ABT) is currently trading below its 50-day and 200-day moving averages ($105.45 and $105.72), indicating a bearish short-term trend. The Relative Strength Index (RSI) at 17.2 is in oversold territory, suggesting a potential for a bounce, though momentum indicators like MACD remain negative. Key support levels are being tested, with the current price of $103.10 near the low end of its trading range. Volume has been slightly below average, offering no strong conviction behind the current price action. The chart structure suggests that a sustained move above the 50-day SMA would be required to signal a shift in momentum.",
    "26 analysts cover ABT with a consensus 'Buy' rating and a median price target of $120, indicating significant upside potential from the current price.",
    "Abbott Laboratories has a history of meeting or exceeding EPS estimates, with the latest quarter showing a 2.34% surprise, suggesting resilient operational performance.",
    "Insiders have sold a net $48.6 million worth of stock, signaling a moderate sell signal and potentially indicating a lack of immediate conviction from management.",
    "The stock is trading below its 50-day and 200-day moving averages ($105.45 and $105.72), with a bearish RSI and MACD, suggesting downward price momentum.",
    "Abbott Laboratories (ABT) is expected to see continued growth, with Wall Street projecting revenue to reach $50.3 billion in the current year, a 13% increase year-over-year, and next year's revenue estimated at $54.6 billion with 9% growth. The company's strong profit margins and consistent earnings beats support a base case scenario where the stock could reach its median analyst target price of $120 within the next 6-12 months. Potential upside catalysts include further innovation in its medical device segments and successful expansion into new markets, which could drive growth beyond current estimates. Conversely, a failure to break its current technical downtrend, increased regulatory scrutiny, or unexpected competitive pressures could lead to a downside scenario, potentially testing the $76.92 level projected by long-range simulations."
   ],
   "lists": {
    "ProTips": [
     "Given the oversold RSI (17.2), consider monitoring for a technical bounce, but confirm with a move above the 50-day SMA ($105.45) before establishing a long position.",
     "While insider selling is notable, the strong analyst consensus and forward-looking growth estimates provide a supportive backdrop for the stock.",
     "As a major player in healthcare, Abbott Laboratories (ABT) is subject to regulatory changes; stay informed on any FDA or international health authority developments."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Analyst Buy Ratings and Price Targets",
     "text": "26 analysts cover ABT with a consensus 'Buy' rating and a median price target of $120, indicating significant upside potential from the current price.",
     "source": "Wall Street Analysts"
    },
    {
     "type": "Bullish",
     "title": "Consistent Earnings Beats",
     "text": "Abbott Laboratories has a history of meeting or exceeding EPS estimates, with the latest quarter showing a 2.34% surprise, suggesting resilient operational performance.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bearish",
     "title": "Insider Net Selling Activity",
     "text": "Insiders have sold a net $48.6 million worth of stock, signaling a moderate sell signal and potentially indicating a lack of immediate conviction from management.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Bearish Technical Indicators",
     "text": "The stock is trading below its 50-day and 200-day moving averages ($105.45 and $105.72), with a bearish RSI and MACD, suggesting downward price momentum.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Abbott Laboratories (ABT) trades at a P/E ratio of 33.36, which is slightly above the sector median of 31.9, but its price-to-sales ratio of 3.83 is in line with the sector average. The company's return on equity stands at a healthy 10.58%, outperforming the sector median of 6.9%. With a profit margin of 11.65%, Abbott demonstrates strong profitability. Its debt-to-equity ratio of 0.63 is also within a reasonable range compared to the sector average. The current valuation appears justified by its strong profitability and growth prospects, especially considering the consistent earnings beats.",
    "Abbott Laboratories (ABT) has a strong track record of meeting or exceeding earnings expectations. In the most recent quarter to June 2026, EPS came in at $1.31, surpassing the estimate of $1.28 by 2.34% and leading to a 1.87% stock price increase. Prior quarters also show consistent performance, with EPS matching estimates or beating them, indicating reliable operational execution.",
    "The primary risk for Abbott Laboratories (ABT) lies in its current technical weakness, trading below key moving averages and showing bearish momentum. Additionally, significant insider selling, with total sales of $48.6 million against $4.4 million in purchases, warrants attention, although the overall verdict is a moderate sell signal. Competition within the medical device sector remains intense, posing a continuous challenge to market share and pricing power."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "178.39B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "33.36"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "3.09"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "2.41%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "137.49"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "81.97"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Oversold SMA Cross Neutral Price vs SMA Bearish MACD Bearish Price is trading below the 50-day SMA, RSI at 17.2 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Neutral",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "17.20"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-0.90"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "105.45"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "105.72"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.11",
    "Correlation with Nasdaq 100 (QQQ)": "-0.03",
    "Correlation with Bitcoin (BTC)": "-0.03",
    "Correlation with Gold (XAU)": "+0.04"
   }
  },
  {
   "id": "trade-plans",
   "title": "ABT Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (17.2) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$106.08",
    "TARGET 2": "$111.13",
    "TARGET 3": "$116.18",
    "STOP LOSS": "$97.69"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+2.75%",
    "Average Feb return": "+0.02%",
    "Average Mar return": "-2.32%",
    "Average Apr return": "+0.61%",
    "Average May return": "-0.07%",
    "Average Jun return": "+2.88%",
    "Average Jul return": "+3.71%",
    "Average Aug return": "+1.36%",
    "Average Sep return": "-0.43%",
    "Average Oct return": "-1.42%",
    "Average Nov return": "+3.14%",
    "Average Dec return": "+1.76%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.35%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in ABT in September 2016 would be worth about $25,071 today, compared with about $35,344 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ABT today could grow to about $22,473 by 2036 in the base case, with a bull case near $59,584 and a bear case around $8,476. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "ABT Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $143 for ABT by 2030 in the base case, from $103 today (1.4x over 4 years). The downside path ends near $76.92. These are outcomes of a Monte Carlo simulation run on ABT's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using ABT's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "ABT simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$82.12",
        "$112",
        "$152"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$78.37",
        "$121",
        "$187"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$77.05",
        "$131",
        "$224"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$76.92",
        "$143",
        "$264"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$77.55",
        "$155",
        "$308"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$78.74",
        "$168",
        "$357"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$80.37",
        "$182",
        "$411"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$82.37",
        "$197",
        "$471"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$84.72",
        "$214",
        "$539"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$87.38",
        "$232",
        "$614"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "ABBV AbbVie Inc. NYSE $263.04 +0.49%",
     "url": "https://clearank.com/stock/abbvie-abbv/"
    },
    {
     "text": "BDX Becton, Dickinson and Company NYSE $185.92 +1.65%",
     "url": "https://clearank.com/stock/bdx-stock-analysis/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $899.56 -1.25%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    },
    {
     "text": "NTRA Natera, Inc. NASDAQ $350.78 +2.63%",
     "url": "https://clearank.com/stock/natera-ntra/"
    },
    {
     "text": "IQV IQVIA Holdings Inc. NYSE $269.67 +1.51%",
     "url": "https://clearank.com/stock/iqvia-iqv/"
    },
    {
     "text": "LLY Eli Lilly and Company NYSE $1,146.56 +0.73%",
     "url": "https://clearank.com/stock/eli-lilly-lly/"
    },
    {
     "text": "A Agilent Technologies, Inc. NYSE $150.27 +2.36%",
     "url": "https://clearank.com/stock/agilent-technologies-a/"
    },
    {
     "text": "SYK Stryker Corp. NYSE $281.50 -0.13%",
     "url": "https://clearank.com/stock/stryker-syk/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "Invesco QQQ vs Vanguard S&P 500 (VOO) Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/qqq-vs-voo/"
    },
    {
     "text": "VTI vs VXUS Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vti-vs-vxus/"
    },
    {
     "text": "MSTR vs COIN Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/mstr-vs-coin/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "ABT Insider Trading Analysis",
   "facts": {
    "Bought": "$4.4M",
    "Sold": "$48.6M",
    "Insiders": "24",
    "Avg Transaction": "$3.1M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in ABT",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Aug 25, 2026",
       "cells": [
        "FORD ROBERT B. Chief Executive Officer",
        "Sell",
        "398.8K",
        "$46.2M"
       ]
      },
      {
       "label": "Feb 5, 2025",
       "cells": [
        "FORD ROBERT B. Chief Executive Officer",
        "Sell",
        "285.4K",
        "$37.4M"
       ]
      },
      {
       "label": "Feb 1, 2021",
       "cells": [
        "ALLEN HUBERT L. Officer",
        "Sell",
        "203.4K",
        "$25.1M"
       ]
      },
      {
       "label": "Jan 30, 2025",
       "cells": [
        "ALLEN HUBERT L. Officer",
        "Sell",
        "189.8K",
        "$24.3M"
       ]
      },
      {
       "label": "Dec 13, 2021",
       "cells": [
        "CAPEK JOHN M Officer",
        "Sell",
        "149.6K",
        "$20.2M"
       ]
      },
      {
       "label": "Oct 21, 2024",
       "cells": [
        "ALLEN HUBERT L. Officer",
        "Sell",
        "157.4K",
        "$18.4M"
       ]
      },
      {
       "label": "Aug 27, 2021",
       "cells": [
        "LANE ANDREW H Executive Vice President",
        "Sell",
        "135.9K",
        "$17.1M"
       ]
      },
      {
       "label": "Sep 12, 2024",
       "cells": [
        "FORD ROBERT B. Chief Executive Officer",
        "Sell",
        "141.7K",
        "$16.5M"
       ]
      },
      {
       "label": "Mar 7, 2025",
       "cells": [
        "EARNHARDT LISA D President",
        "Sell",
        "91.4K",
        "$12.2M"
       ]
      },
      {
       "label": "Apr 30, 2021",
       "cells": [
        "WATKIN JARED L Officer",
        "Sell",
        "94.6K",
        "$11.3M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Abbott+Laboratories&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Abbott Laboratories' stock forecast for 2030?",
   "answer": "Abbott Laboratories' (ABT) stock forecast for 2030, based on Monte Carlo simulations, projects a base case price of $142.52, with a downside scenario of $76.92 and an upside scenario of $264.06. These are statistical outcomes, not guarantees."
  },
  {
   "question": "Is Abbott Laboratories stock a buy right now?",
   "answer": "Abbott Laboratories (ABT) is currently rated a 'Buy' by Wall Street analysts, with a consensus score of 74 out of 100. The median analyst price target of $120 suggests a potential upside of 16.4% from the current price of $103.10."
  },
  {
   "question": "What are the key technical levels for Abbott Laboratories stock?",
   "answer": "Abbott Laboratories (ABT) is currently trading below its 50-day SMA of $105.45 and its 200-day SMA of $105.72, indicating bearish short-term trends. The RSI is oversold at 17.2, suggesting a potential for a rebound, but confirmation requires a move back above these key moving averages."
  },
  {
   "question": "How has Abbott Laboratories performed in recent earnings reports?",
   "answer": "Abbott Laboratories (ABT) has consistently met or exceeded earnings expectations. The latest quarter to June 2026 saw EPS of $1.31 against an estimate of $1.28, a 2.34% surprise, and the stock reacted positively. Previous quarters also show a pattern of meeting or beating estimates."
  },
  {
   "question": "What is the insider sentiment for Abbott Laboratories?",
   "answer": "Insider sentiment for Abbott Laboratories (ABT) is currently a 'moderate sell signal,' with total insider sales of $48.6 million compared to total purchases of $4.4 million in recent filings. This indicates a net selling pressure from insiders."
  },
  {
   "question": "How does Abbott Laboratories compare to its sector peers?",
   "answer": "Abbott Laboratories (ABT) shows a higher P/E ratio (33.36) than the sector median (31.9) but offers a stronger return on equity (10.58% vs. 6.9%). Its revenue growth of 13% also surpasses the sector median of 8.1%, suggesting it is outperforming peers in growth despite a slightly higher valuation multiple."
  },
  {
   "question": "What are the main risks facing Abbott Laboratories?",
   "answer": "Key risks for Abbott Laboratories (ABT) include its current bearish technical trend, significant insider selling activity, and intense competition within the medical device industry. A sustained move below key support levels could exacerbate downward price pressure."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "ABBV",
    "name": "AbbVie Inc. NYSE",
    "price": "$263.04",
    "change": "+0.49%",
    "url": "https://clearank.com/stock/abbvie-abbv/"
   },
   {
    "ticker": "BDX",
    "name": "Becton, Dickinson and Company NYSE",
    "price": "$185.92",
    "change": "+1.65%",
    "url": "https://clearank.com/stock/bdx-stock-analysis/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$899.56",
    "change": "-1.25%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   },
   {
    "ticker": "NTRA",
    "name": "Natera, Inc. NASDAQ",
    "price": "$350.78",
    "change": "+2.63%",
    "url": "https://clearank.com/stock/natera-ntra/"
   },
   {
    "ticker": "IQV",
    "name": "IQVIA Holdings Inc. NYSE",
    "price": "$269.67",
    "change": "+1.51%",
    "url": "https://clearank.com/stock/iqvia-iqv/"
   },
   {
    "ticker": "LLY",
    "name": "Eli Lilly and Company NYSE",
    "price": "$1,146.56",
    "change": "+0.73%",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "A",
    "name": "Agilent Technologies, Inc. NYSE",
    "price": "$150.27",
    "change": "+2.36%",
    "url": "https://clearank.com/stock/agilent-technologies-a/"
   },
   {
    "ticker": "SYK",
    "name": "Stryker Corp. NYSE",
    "price": "$281.50",
    "change": "-0.13%",
    "url": "https://clearank.com/stock/stryker-syk/"
   }
  ],
  "comparisons": [
   {
    "ticker": "Invesco QQQ vs Vanguard S&P 500 (VOO) Comparison",
    "name": "",
    "url": "https://clearank.com/compare/qqq-vs-voo/"
   },
   {
    "ticker": "VTI vs VXUS Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vti-vs-vxus/"
   },
   {
    "ticker": "MSTR vs COIN Comparison",
    "name": "",
    "url": "https://clearank.com/compare/mstr-vs-coin/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "KMB",
    "text": "Kimberly-Clark Corporation",
    "url": "https://clearank.com/stock/kmb-stock-analysis/"
   },
   {
    "ticker": "IAUM",
    "text": "iShares Gold Trust Micro",
    "url": "https://clearank.com/etf/iaum-etf-analysis/"
   },
   {
    "ticker": "SLVR",
    "text": "Sprott Silver Miners & Physical Silver ETF",
    "url": "https://clearank.com/etf/slvr-etf-analysis/"
   },
   {
    "ticker": "NTES",
    "text": "NetEase, Inc.",
    "url": "https://clearank.com/stock/ntes-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "QRVO",
    "text": "↑ 9.34%",
    "url": "https://clearank.com/stock/qorvo-qrvo/"
   },
   {
    "ticker": "RAY/USD",
    "text": "↓ 9.20%",
    "url": "https://clearank.com/crypto/raydium-ray-usd/"
   },
   {
    "ticker": "EGLD/USD",
    "text": "↓ 9.14%",
    "url": "https://clearank.com/crypto/egld-usd-crypto-analysis/"
   },
   {
    "ticker": "ARB/USD",
    "text": "↑ 19.42%",
    "url": "https://clearank.com/crypto/arbitrum-arb-usd/"
   },
   {
    "ticker": "WING",
    "text": "↓ 12.09%",
    "url": "https://clearank.com/stock/wingstop-wing/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "BSX",
    "text": "Boston Scientific Corporation",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "DXCM",
    "text": "DexCom",
    "url": "https://clearank.com/stock/dxcm-stock-analysis/"
   },
   {
    "ticker": "EW",
    "text": "Edwards Lifesciences Corporation",
    "url": "https://clearank.com/stock/ew-stock-analysis/"
   },
   {
    "ticker": "GEHC",
    "text": "GE HealthCare",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "MDT",
    "text": "Medtronic plc",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/abt.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/abt.png",
     "width": "1280",
     "height": "720",
     "caption": "Abbott Laboratories (ABT) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/abbott-laboratories-abt/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/abbott-laboratories-abt/",
        "name": "Abbott Laboratories (ABT) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/abbott-laboratories-abt/#webpage",
     "url": "https://clearank.com/stock/abbott-laboratories-abt/",
     "name": "Abbott Laboratories (ABT) Stock Forecast (2026)",
     "datePublished": "2026-06-29T09:32:58+00:00",
     "dateModified": "2026-09-15T11:46:10+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/abt.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/abbott-laboratories-abt/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/abbott-laboratories-abt/#richSnippet",
     "headline": "Abbott Laboratories (ABT) Stock Forecast (2026)",
     "name": "Abbott Laboratories (ABT) Stock Forecast (2026)",
     "description": "Abbott Laboratories (ABT) stock: Healthcare, Medical Devices. $178.4B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-06-29T09:32:58+00:00",
     "dateModified": "2026-09-15T11:46:10+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Abbott Laboratories",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "ABT"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of medical devices, diagnostic systems, nutritional products, and branded generic medicines. Its portfolio spans cardiovascular care, diabetes management, electrophysiology, structural heart, ne",
      "tickerSymbol": "ABT",
      "sameAs": "https://www.abbott.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/abbott-laboratories-abt/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/abt.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/abbott-laboratories-abt/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Abbott Laboratories' stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Abbott Laboratories' (ABT) stock forecast for 2030, based on Monte Carlo simulations, projects a base case price of $142.52, with a downside scenario of $76.92 and an upside scenario of $264.06. These are statistical outcomes, not guarantees."
     }
    },
    {
     "@type": "Question",
     "name": "Is Abbott Laboratories stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Abbott Laboratories (ABT) is currently rated a 'Buy' by Wall Street analysts, with a consensus score of 74 out of 100. The median analyst price target of $120 suggests a potential upside of 16.4% from the current price of $103.10."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical levels for Abbott Laboratories stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Abbott Laboratories (ABT) is currently trading below its 50-day SMA of $105.45 and its 200-day SMA of $105.72, indicating bearish short-term trends. The RSI is oversold at 17.2, suggesting a potential for a rebound, but confirmation requires a move back above these key moving averages."
     }
    },
    {
     "@type": "Question",
     "name": "How has Abbott Laboratories performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Abbott Laboratories (ABT) has consistently met or exceeded earnings expectations. The latest quarter to June 2026 saw EPS of $1.31 against an estimate of $1.28, a 2.34% surprise, and the stock reacted positively. Previous quarters also show a pattern of meeting or beating estimates."
     }
    },
    {
     "@type": "Question",
     "name": "What is the insider sentiment for Abbott Laboratories?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider sentiment for Abbott Laboratories (ABT) is currently a 'moderate sell signal,' with total insider sales of $48.6 million compared to total purchases of $4.4 million across 54 transactions. This indicates a net selling pressure from insiders."
     }
    },
    {
     "@type": "Question",
     "name": "How does Abbott Laboratories compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Abbott Laboratories (ABT) shows a higher P/E ratio (33.36) than the sector median (31.9) but offers a stronger return on equity (10.58% vs. 6.9%). Its revenue growth of 13% also surpasses the sector median of 8.1%, suggesting it is outperforming peers in growth despite a slightly higher valuation multiple."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing Abbott Laboratories?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks for Abbott Laboratories (ABT) include its current bearish technical trend, significant insider selling activity, and intense competition within the medical device industry. A sustained move below key support levels could exacerbate downward price pressure."
     }
    }
   ]
  }
 ]
}